(ABBV) AbbVie - Ratings and Ratios

AbbVie Inc. (NYSE:ABBV) is a research-driven biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapies. Since its inception in 2012, the company has established a strong portfolio addressing multiple therapeutic areas, including immunology, oncology, aesthetics, neuroscience, eye care, and virology. AbbVie is headquartered in North Chicago, Illinois, and operates globally, with a focus on improving patient outcomes through advanced medical solutions.

The companys immunology portfolio includes key products such as Humira, a widely used biologic for autoimmune diseases; Skyrizi and Rinvoq, next-generation therapies for autoimmune conditions; and Ubrelvy and Qulipta for migraine treatment. In oncology, AbbVie offers targeted therapies like Imbruvica, Venclexta/Venclyxto, and Elahere, addressing various blood cancers and solid tumors. Its aesthetics division includes facial injectables and skincare products, while its neuroscience segment features treatments for conditions like Parkinsons disease, schizophrenia, and chronic migraine.

AbbVie also has a robust pipeline in eye care, with products such as Ozurdex and Restasis for conditions like glaucoma and dry eye syndrome. In virology, the company markets Mavyret/Maviret for hepatitis C and maintains a presence in gastrointestinal health with Creon and Linzess/Constella for digestive disorders. AbbVies commitment to innovation is supported by significant R&D investments, aiming to address unmet medical needs and expand its therapeutic offerings.

Ticker Symbol: ABBV Exchange: NYSE Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology Resistance: 199.8 Resistance: 190.3 Resistance: 174.8 Support: 166.1 Support: 159.2 Support: 154.6 Average Volume 20d: 9155254 Last Price: 172.99 SMA 20: 190.05 SMA 50: 197.71 SMA 200: 184.54 ATR: 6.97 Market Cap: 318132.75M USD P/E: 75.09 P/E Forward: 14.64 P/B: 95.68 P/S: 5.65 RoE: 128.66

3-Month Forecast: Based on and , AbbVies stock is likely to face near-term headwinds due to its current price sitting below the SMA 20 and SMA 50. The ATR of 6.97 suggests moderate volatility. However, the companys strong fundamental position, highlighted by a high RoE of 128.66 and a forward P/E of 14.64, indicates potential for recovery. In the first month, the stock may test support at 166.1. If this level holds, stabilization is expected in the second month. By the third month, AbbVie could rebound, driven by its robust earnings outlook and pipeline advancements.